Diabetes · SGLT2 InhibitorRegulatory Approvalcommercialmid-term

FDA Submission Update for Canagliflozin by Teva Pharmaceuticals

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/29/2026, 6:01:56 AM

Assessment confidence: 69% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Teva Pharmaceuticals' submission for Canagliflozin under ANDA210451 signals a significant shift in the competitive landscape of the SGLT2 inhibitor market. This could lead to increased pricing pressure and necessitates a reevaluation of market strategies for existing players in this therapeutic area. Regulatory context from FDA (FDA TA — CANAGLIFLOZIN (ORIG)) supports the near-term read. Assessment grounded in 18 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Teva's entry on market dynamics and pricing strategies for existing SGLT2 inhibitors. The strongest clinical anchor is A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) (ClinicalTrials.gov), sponsor/company relevance (merck). In Diabetes · SGLT2 Inhibitor, 5 regulatory and 4 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Approves Canagliflozin Application by Aurobindo Pharma. This submission indicates Teva's entry into the SGLT2 inhibitor market, potentially increasing competition against established players.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — CANAGLIFLOZIN (ORIG) (FDA). Entity match (teva); Regulatory pathway relevance (nda). The application is currently under standard review, and the outcome will determine the regulatory landscape for SGLT2 inhibitors, impacting compliance and market access.

Key Risks

Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Teva's entry could disrupt market share and pricing strategies for established SGLT2 inhibitors, potentially affecting revenue streams for current market leaders.
Upside for Teva may improve if A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov) delivers favorable follow-through.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Portfolio teams should assess the impact of Teva's entry on market dynamics and pricing strategies for existing SGLT2 inhibitors.

What Would Change This Assessment

This becomes more urgent if Monitor the review timeline and any potential approval outcomes for ANDA210451.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — CANAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — CANAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CANAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (canagliflozin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CANAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (canagliflozin); Regulatory pathway relevance (nda)
FDA document
View source
FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves Canagliflozin Application by Aurobindo Pharma
Humanexa Signalshigh relevance
Entity match (canagliflozin)
FDA Grants Priority Review for TZIELD (Teplizumab) Supplement
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA Grants Approval for Glycerol Phenylbutyrate by Teva Pharmaceuticals
Humanexa Signalshigh relevance
Entity match (teva)

Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva
Canagliflozin

Commercial impact

medium

Teva's entry could disrupt market share and pricing strategies for established SGLT2 inhibitors, potentially affecting revenue streams for current market leaders.

Regulatory impact

medium

The application is currently under standard review, and the outcome will determine the regulatory landscape for SGLT2 inhibitors, impacting compliance and market access.

What to watch

Monitor the review timeline and any potential approval outcomes for ANDA210451.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.